Adaptive Biotechnologies Corporation
NMS: ADPTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Adaptive Biotechnologies Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get ADPT Z-Score →About Adaptive Biotechnologies Corporation
Healthcare
Biotechnology
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
📊 Fundamental Analysis
Adaptive Biotechnologies Corporation demonstrates a profit margin of -21.5%, which is below the sector average, suggesting competitive pressure.
The company recently reported 51.0% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -27.8%, which indicates that capital utilization is currently under pressure.
At a current price of $12.79, ADPT currently sits at the 43rd percentile of its 52-week range (Range: $6.78 - $20.76).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$1.97B
Trailing P/E
--
Forward P/E
-47.37
Beta (5Y)
2.30
52W High
$20.76
52W Low
$6.78
Avg Volume
2.00M
Day High
Day Low